PDCD1 and cancer: Taken together, evidence across cancer types suggests that PD-1 inhibitors generally preserve or enhance HRQL relative to older standard-of-care chemotherapy, presenting with fewer of the debilitating day-to-day effects, yet still achieving durable clinical responses.